- Home
- About drugs
- NDF A-Z listing
- Fluticasone Furoate + Umeclidinium + Vilanterol
F
Fluticasone Furoate + Umeclidinium + Vilanterol
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredients: Fluticasone | Umeclidinium | Vilanterol
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
17/02/2025 Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
The Ministry of Health’s Drug Advisory Committee has recommended:
Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder for treating asthma; and
Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) inhalation powder for treating chronic obstructive pulmonary disease.
Funding status
[R] Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder are recommended for inclusion on the Standard Drug List (SDL) for the abovementioned indications from 1 April 2025.
[NR] SDL subsidy does not apply to any formulations or strengths of beclomethasone dipropionate/glycopyrronium/formoterol, budesonide/glycopyrronium/formoterol, mometasone furoate/glycopyrronium/indacaterol, or tiotropium.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Drug availability
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Powder, Metered, Fluticasone Furoate (Micronised) 100 mcg + Umeclidinium 62.5 mcg + Vilanterol 25 mcg |
|
Powder, Metered, Fluticasone Furoate (Micronised) 200 mcg + Umeclidinium 62.5 mcg + Vilanterol 25 mcg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Respiratory (Inhalation)
TRELEGY ELLIPTA INHALATION POWDER 100 MCG/62.5 MCG/25 MCG [SIN15806P]
TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5 MCG/25 MCG [SIN16914P]